Sofinnova Investments related stories
All articles and analysis
Phenomix Partners with Forest Labs, After Canceling IPOPhenomix Corp. has signed a collaboration deal with Forest Laboratories Inc. (NYSE: FRX), to develop and commercialize dutogliptin, Phenomix’ orally-administered DPP-4 inhibitor that is currently undergoing Phase 3 clinical trials in Type 2 diabetes mellitus. The entire deal could be worth $340 million for Phenomix, including a $75 million up-front cash payment. San Diego-based Phenomix earlier this week canceled an IPO, and has raised around $125 million in total VC funding since its 2001 founding, from firms like JPMorgan Partners (18% pre-IPO stake), Nomura Phase4 Ventures (15.8%), Delphi Ventures (11.1%), Alta Partners (9.8%), Sofinnova Ventures (9.8%), Novartis BioVenture Fund (9.1%), Baker Brothers (7.6%), Bay City Capital (6.5%), CMEA Ventures (5.8%) and GBS Venture Partners.
- PE Week Wire: Friday, October 24, 2008
peHUB Presidential Poll Results
- PE Week Wire: Friday, October 24, 2008
peHUB Presidential Poll Results
- PE Week Wire: Thursday, October 23, 2008
Random Ramblings
- KaloBios raises cash, sans Lehman Brothers
Lehman still holds shares in antibody developer
- Week in deals, Sept. 29, 2008
News and notes for tech companies and other businesses that raised financing in North America in the past week
- Executive moves, week of Sept. 29, 2008
Hires and other changes at Norwest, Greenpark, Polaris, Evercore, H.I.G. and other venture capital and private equity firms
- Exit watch, week of Sept. 29, 2008
News about venture-backed Prestwick Pharma and other companies that were acquired in the last week
- KaloBios Raises $20 Million
KaloBios Pharmaceuticals Inc., a South San Francisco-based developer of antibody therapeutics, has raised $20 million in the first close of its Series D funding round. Mitsubishi UFJ Capital and Genzyme Corp. co-led the round, and were joined by return backers MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, Pte., 5AM Ventures and Lotus Bioscience Ventures.